Literature DB >> 21217014

Absent bactericidal activity of mouse serum against invasive African nontyphoidal Salmonella results from impaired complement function but not a lack of antibody.

Matthew K Siggins1, Adam F Cunningham, Jennifer L Marshall, Jayne L Chamberlain, Ian R Henderson, Calman A MacLennan.   

Abstract

Nontyphoidal strains of Salmonella are a major cause of fatal bacteremia in Africa. Developing a vaccine requires an improved understanding of the relevant mechanisms of protective immunity, and the mouse model of Salmonella infection is useful for studying immunity to Salmonella in vivo. It is important to appreciate the similarities and differences between immunity to Salmonella in mice and men. Ab is important for protection against nontyphoidal Salmonella in both species, and we have previously found an important role for Ab in cell-free complement-mediated bactericidal activity against Salmonella in Africans. It is unclear whether this modality of immunity is relevant in the mouse model. C57BL/6, BALB/c, and C3H mice immunized with heat-killed Salmonella Typhimurium strains D23580 (African invasive strain) and SL1344 and live-attenuated strain SL3261 produced a Salmonella-specific Ab response. Sera from these mice deposited reduced levels of C3 on Salmonella compared with human sera and were unable to kill both wild-type and galE(-) rough mutant of D23580, indicating absent cell-free killing via classical and alternative complement pathways. Supplementing immune mouse sera with human complement enabled killing of Salmonella, whereas addition of human anti-Salmonella Ab to immune mouse sera had no effect. These findings indicate that mouse serum cannot effect [corrected] cell-free complement-dependent killing of Salmonella, because of the reduced mouse complement ability to kill these bacteria compared with human complement. This difference in Ab-dependent immunity to Salmonella in mice and men must be considered when applying findings from the mouse model of Salmonella disease and vaccination response to man.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21217014     DOI: 10.4049/jimmunol.1000284

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  30 in total

Review 1.  Antibody-Dependent Enhancement of Bacterial Disease: Prevalence, Mechanisms, and Treatment.

Authors:  Von Vergel L Torres; Carrie F Coggon; Timothy J Wells
Journal:  Infect Immun       Date:  2021-03-17       Impact factor: 3.441

2.  The O-Antigen Capsule of Salmonella enterica Serovar Typhimurium Facilitates Serum Resistance and Surface Expression of FliC.

Authors:  Joanna M Marshall; John S Gunn
Journal:  Infect Immun       Date:  2015-07-20       Impact factor: 3.441

3.  Identification of a common immune signature in murine and human systemic Salmonellosis.

Authors:  Seung-Joo Lee; Li Liang; Silvia Juarez; Minelva R Nanton; Esther N Gondwe; Chisomo L Msefula; Matthew A Kayala; Francesca Necchi; Jennifer N Heath; Peter Hart; Renée M Tsolis; Robert S Heyderman; Calman A MacLennan; Philip L Felgner; D Huw Davies; Stephen J McSorley
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-13       Impact factor: 11.205

4.  IL-7 Enables Antibody Responses to Bacterial Polysaccharides by Promoting B Cell Receptor Diversity.

Authors:  Gregory S Dickinson; Eric A Levenson; Justin A Walker; John F Kearney; Kishore R Alugupalli
Journal:  J Immunol       Date:  2018-07-13       Impact factor: 5.422

5.  Serum bactericidal assays to evaluate typhoidal and nontyphoidal Salmonella vaccines.

Authors:  Mary Adetinuke Boyd; Sharon M Tennant; Venant A Saague; Raphael Simon; Khitam Muhsen; Girish Ramachandran; Alan S Cross; James E Galen; Marcela F Pasetti; Myron M Levine
Journal:  Clin Vaccine Immunol       Date:  2014-03-12

6.  YraP Contributes to Cell Envelope Integrity and Virulence of Salmonella enterica Serovar Typhimurium.

Authors:  Faye C Morris; Timothy J Wells; Jack A Bryant; Anna E Schager; Yanina R Sevastsyanovich; Derrick J P Squire; Jennifer Marshall; Georgia L Isom; Jessica Rooke; Riyaz Maderbocus; Timothy J Knowles; Michael Overduin; Amanda E Rossiter; Adam F Cunningham; Ian R Henderson
Journal:  Infect Immun       Date:  2018-10-25       Impact factor: 3.441

7.  Terminal Deoxynucleotidyl Transferase Is Not Required for Antibody Response to Polysaccharide Vaccines against Streptococcus pneumoniae and Salmonella enterica Serovar Typhi.

Authors:  Vivek Belde; Matthew P Cravens; Dania Gulandijany; Justin A Walker; Isabel Palomo-Caturla; Akhil S Alugupalli; Vijay K Sandilya; Tamer Mahmoud; Andreas J Bäumler; John F Kearney; Kishore R Alugupalli
Journal:  Infect Immun       Date:  2018-08-22       Impact factor: 3.441

8.  Live attenuated S. Typhimurium vaccine with improved safety in immuno-compromised mice.

Authors:  Balamurugan Periaswamy; Lisa Maier; Vikalp Vishwakarma; Emma Slack; Marcus Kremer; Helene L Andrews-Polymenis; Michael McClelland; Andrew J Grant; Mrutyunjay Suar; Wolf-Dietrich Hardt
Journal:  PLoS One       Date:  2012-09-24       Impact factor: 3.240

9.  The stability of complement-mediated bactericidal activity in human serum against Salmonella.

Authors:  Colette M O'Shaughnessy; Adam F Cunningham; Calman A Maclennan
Journal:  PLoS One       Date:  2012-11-08       Impact factor: 3.240

10.  Monoclonal Antibodies of a Diverse Isotype Induced by an O-Antigen Glycoconjugate Vaccine Mediate In Vitro and In Vivo Killing of African Invasive Nontyphoidal Salmonella.

Authors:  Yun Shan Goh; Simon Clare; Francesca Micoli; Allan Saul; Pietro Mastroeni; Calman A MacLennan
Journal:  Infect Immun       Date:  2015-07-13       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.